Curanex Pharmaceuticals Inc
curanexpharma.comWhat Do They Do?
Develops botanical drug candidates, led by Phyto-N, for patients with inflammatory diseases.
10-K for FY2025, filed Mar 30, 2026
Sources
Who Are Their Customers?
If approved, it expects to sell drug products to healthcare providers, specialty pharmacies, and distributors. It also plans to pursue collaborations and licensing agreements with other pharmaceutical companies.
10-K for FY2025, filed Mar 30, 2026
Sources
How Are They Changing?
Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$3.3MView ↗
- ▲ +5354% (Loss)
- vs −$60.3K in Q2 FY2025
-
May 14, 2026
Adds cancer cachexia to its development pipeline
The company intends to evaluate the indication through additional development planning and future research.
Sources
8-K, filed May 14, 2026
Following the end of the first quarter, Curanex expanded its pipeline strategy to include cancer cachexia as a new core indication.View ↗
Loading...
Comments
